Product Description
Eptifibatide is an inhibitor of platelet aggregation belonging to the class of RGD (arginine-glycine-aspartate) mimetics.
Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor and other adhe
AI Product Description
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Eptifibatide is a synthetic cyclic heptapeptide mimicking the KGD motif of fibrinogen, serving as a potent <strong>GPIIb/IIIa inhibitor</strong>. Produced via solid-phase peptide synthesis, it prevents platelet aggregation. Molecular formula: C<sub>35</sub>H<sub>49</sub>N<sub>11</sub>O<sub>10</sub>S; CAS No.: 168273-52-9.</p>
<h3>Application</h3>
<ul>
<li><strong>Cardiology:</strong> Adjunct therapy in unstable angina and non-ST-elevation myocardial infarction.</li>
<li><strong>Percutaneous Coronary Intervention (PCI):</strong> Prevents thrombotic complications during angioplasty.</li>
<li><strong>Pharmaceutical Manufacturing:</strong> Bulk active ingredient for injectable formulations.</li>
</ul>
<h3>Precautions</h3>
<p>Contraindicated in patients with active internal bleeding or history of hemorrhagic stroke. Strictly store at 2°C to 8°C in lyophilized form. Monitor platelet counts closely to avoid severe thrombocytopenia.</p>